Reduced peak, but no diurnal variation, in thrombin generation upon melatonin supplementation in tetraplegia

Summary

Tetraplegic patients have increased risk of venous thrombosis despite anti-thrombotic prophylaxis. Moreover, they have blunted plasma variations in melatonin and altered diurnal variation of several haemostatic markers, compared with able-bodied. However, whether healthy individuals and tetraplegic patients, with or without melatonin, display abnormalities in thrombin generation during a 24-hour (h) cycle, is unknown. We therefore used the Calibrated Automated Thrombogram (CAT) assay to examine diurnal variations and the possible role of melatonin in thrombin generation. Six men with long-standing complete tetraplegia were included in a randomised placebo-controlled cross-over study with melatonin supplementation (2 mg, 4 consecutive nights), whereas six healthy, able-bodied men served as controls. Ten plasma samples were collected frequently during a 24-h awake/sleep cycle. No significant diurnal variation of any of the measured CAT indices was detected in the three study groups. Whereas endogenous thrombin potential (ETP) was independent (p > 0.05) of whether the tetraplegic men received melatonin or placebo, melatonin decreased (p = 0.005) peak values in tetraplegia compared with those given placebo. Able-bodied men had lower (p = 0.019) ETP and Lag-Time (p = 0.018) compared with tetraplegics receiving placebo. Neither the Time-to-Peak nor the Start-Tail was affected (p > 0.05) by melatonin in tetraplegia. In conclusion, indices of thrombin generation are not subjected to diurnal variation in healthy able-bodied or tetraplegia, but peak thrombin generation is reduced in tetraplegic men receiving oral melatonin.

Keywords

Diurnal rhythm - haemostasis - melatonin - nervous system - thrombin

• References

• 1 Green D, Sullivan S, Simpson J. et al. Evolving risk for thromboembolism in spinal cord injury (SPIRATE Study). Am J Phys Med Rehabil 2005; 84: 420-422.
• 2 Jones T, Ugalde V, Franks P. et al. Venous thromboembolism after spinal cord injury: incidence, time course, and associated risk factors in 16,240 adults and children. Arch Phys Med Rehabil 2005; 86: 2240-2247.
• 3 McKinley WO, Jackson AB, Cardenas DD. et al. Long-term medical complications after traumatic spinal cord injury: a regional model systems analysis. Arch Phys Med Rehabil 1999; 80: 1402-1410.
• 4 White RH. The epidemiology of venous thromboembolism. Circulation 2003; 107: I4-8.
• 5 Iversen PO, Groot PD, Hjeltnes N. et al. Impaired circadian variations of haemostatic and fibrinolytic parameters in tetraplegia. Br J Haematol 2002; 119: 1011-1016.
• 6 Dahm AE, Iversen PO, Hjeltnes N. et al. Differences in circadian variations of tissue factor pathway inhibitor type 1 between able-bodied and spinal cord injured. Thromb Res 2006; 118: 281-287.
• 7 Zeitzer JM, Ayas NT, Shea SA. et al. Absence of detectable melatonin and preservation of cortisol and thyrotropin rhythms in tetraplegia. J Clin Endocrinol Metab 2000; 85: 2189-2196.
• 8 Dahm A, Osterud B, Hjeltnes N. et al. Opposite circadian rhythms in melatonin and tissue factor pathway inhibitor type 1: does daylight affect coagulation?. J Thromb Haemost 2006; 4: 840-1842.
• 9 Kostovski E, Dahm AE, Iversen N. et al. Melatonin stimulates release of tissue factor pathway inhibitor from the vascular endothelium. Blood Coag Fibrin 2011; 22: 254-259.
• 10 Perrin J, Depasse F, Lecompte T. Large external quality assessment survey on thrombin generation with CAT: further evidence for the usefulness of normalisation with an external reference plasma. Thromb Res 2015; 136: 125-130.
• 11 Sonnevi K, Tchaikovski SN, Holmstrom M. et al. Obesity and thrombin-generation profiles in women with venous thromboembolism. Blood Coag Fibrin 2013; 24: 547-553.
• 12 Al Dieri R, de Laat B, Hemker HC. Thrombin generation: what have we learned?. Blood Rev 2012; 26: 197-203.
• 13 Kostovski E, Sandset Per M, Iversen PO. et al. Circadian rhythms of hemostatic factors in tetraplegia: a double-blind, randomized, placebo-controlled crossover study of melatonin. Spinal Cord 2015; 53: 285-290.
• 14 Hemker HC, Giesen P, Al Dieri R. et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haem Thromb 2003; 33: 4-15.
• 15 Maynard Jr. FM, Bracken MB, Creasey G. et al. International Standards for Neurological and Functional Classification of Spinal Cord Injury. American Spinal Injury Association. Spinal Cord 1997; 35: 266-274.
• 16 Deguchi K, Noguchi M, Yuwasaki E. et al. Dynamic fluctuations in blood of thrombin/antithrombin III complex (TAT). Am J Hem 1991; 38: 86-89.
• 17 Wirtz PH, Spillmann M, Bartschi C. et al. Oral melatonin reduces blood coagulation activity: a placebo-controlled study in healthy young men. J Pineal Res 2008; 44: 127-133.
• 18 Wirtz PH, Bartschi C, Spillmann M. et al. Effect of oral melatonin on the procoagulant response to acute psychosocial stress in healthy men: a randomized placebo-controlled study. J Pineal Res 2008; 44: 358-365.
• 19 Wirtz PH, Spillmann M, Bartschi C. et al. Oral melatonin reduces blood coagulation activity: a placebo-controlled study in healthy young men. J Pineal Res 2008; 44: 127-133.